2023 ACCP Clinical Practice Webinar | Leveraging Novel Microbiome-related Therapies - On Demand
ACCP 2023 Clinical Practice Webinar - Leveraging Novel Microbiome-related Therapies-On Demand
On-demand webinar recording: May 24, 2023 to May 24, 2026
Why is this article important to your practice?
This clinical webinar will introduce the gut-brain axis including an overall perspective with relevant publications. The presentation will also discuss the link between the gut-brain, alcohol and other addiction (eating) disorders including examples of gut-brain-related neuroendocrine pathways (e.g., ghrelin, GLP-1) that may be relevant in the development of neuro-behavioral conditions such as addiction. Preliminary rat results will be presented from observations of binge-like alcohol drinking leading to changes in the gut microbiome in a manner independent from the presence or not (knock-out) of the ghrelin receptor. Additionally, results from a recently-published manuscript investigating the gut microbiome and metabolome of binge-drinking primates will be reviewed. Speakers will introduce an unpublished clinical protocol and will present preliminary gut microbiome data investigating the gut microbiome of abstinent and currently drinking individuals with alcohol use disorder (AUD) and controls.
Physicians, Pharmacists, PhDs and healthcare professionals interested in clinical pharmacology.
After completing this activity, the learner will be able to:
1. Identify the broad characterization of pathology associated with microbiome changes in several neurological conditions;
2. Estimate the correlations of microbial changes in neuro-behavioral statuses like eating disorders and AUD;
3. Assess why periodontitis is more common in AUD and compare the abundances of health- and periodontitis-associated previously identified genera to those in individuals with AUD;
4. Explore the influence of alcohol consumption and type of drinking and observe longitudinal-temporal changes in the oral microbiome in newly abstinent individuals undergoing inpatient treatment for AUD.
Lorenzo Leggio, MD, MPH
Clinical Director & Deputy Scientific Director, NIDA, Branch Chief
Dr. Lorenzo Leggio is a Senior Investigator (Clinical) and Branch Chief in the NIH Intramural Research Program (IRP) with faculty appointments both at NIDA and NIAAA. He serves as Chief of the Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, a joint NIDA and NIAAA laboratory. He also serves as the NIDA Clinical Director and Deputy Scientific Director, plus other leadership roles within the NIH.. Dr. Leggio received his M.D. and Ph.D. from the Catholic University of Rome, where he also completed residency and received Board Certification in Internal Medicine. He was a postdoctoral research associate in Psychiatry and Human Behavior at Brown University, Providence, RI. In 2010, he joined the faculty of the Brown University Medical School as Assistant Professor and Core Faculty at the Brown Center for Alcohol and Addiction Studies, where he still holds an adjunct appointment as Professor in Behavioral and Social Sciences. He is also an Adjunct Professor of Addiction Medicine at Johns Hopkins University and of Neuroscience at Georgetown University. Dr. Leggio, together with his team, colleagues and collaborators have pioneered and conducted work on medication development, on the role of the microbiome-gut-liver-brain axis and on the role of neuroendocrine pathways in addictive behaviors via human laboratory studies and clinical trials as well as via translational and reverse translational experimental medicine approaches.
Lorenzo Leggio, MD, MPH, Clinical Director & Deputy Scientific Director, NIDA, Branch Chief, NIDA/NIAAA has no relevant financial relationship(s) with ineligible companies to disclose.
Jennifer J. Barb, PhD
Translational Bioinformatics Scientist
National Inst of Health
Dr. Jennifer Barb has been a bioinformatics scientist at the NIH for over 20 years and is currently the unit head of the Data Analytics and Translational Science in the Translational Biobehavioral and Health Disparities Branch at the NIH Clinical Center. Dr. Barb has a wide range of experience in investigating human clinical data and high-throughput gene expression analysis. She has been studying the oral and gut microbiome of individuals with Alcohol Use Disorder and also the role of nutrition and sleep on the addiction for over 8 years. Throughout her career at the NIH, she has collaborated with many intramural institutes including the Forsyth Institute and the Framingham Heart Study. She has coauthored over 50 peer-reviewed publications.
Jennifer J. Barb, PhD, Translational Bioinformatics Scientist, National Inst of Health has no relevant financial relationship(s) with ineligible companies to disclose.
|Access Date||Quiz Result||Score||Actions|